Abstract

Background: Current treatment with statins has become an integral part of vascular diseases but monotherapy has a significant residual event rate. Due to particularly one of the factor associated with atherogenic lipid phenotype that is characterized by a low high-density lipoprotein (HDL) cholesterol and increase in non-HDL cholesterol like Low-Density Lipoprotein (LDL). Omega-3 Fatty acids have demonstrated a preventiverole in primary and, particularly secondary cardiovascular diseases. Hence this study was planned to compare the efficacy of Atorvastatin alone with Atorvastatin and Omega-3 fatty acids in treatment in hyperlipidaemia patients.
 Methods: The study was comparative, randomized, and prospective and open labeled conducted in MI patients. A total of 100 patients were selected based on inclusion and exclusion criteria. They were divided randomly into two Groups (Group–A and Group-B). Group-A was given Atorvastatin 10mg/day and Group-B was given Atorvastatin 10mg/day and Omega-3 fatty acids 600mg/day for 6 months. Follow up was done every month and efficacy was measured by assessing the lipoprotein levels in serum.
 Results: The results were compared before treatment and after 6 months treatment.The levels were significantly decreased Total Cholesterol (TC), LDL, Low-Density Lipoprotein (VLDL), Triglycerides (TG) and HDL levels were increased in Group–A and Group-B. When these results compared between two Groups the HDL levels were increased also it shown high significance (<0.001) but there were no significance changes in other cholesterol levels.
 Conclusion: The present study results showed that Atorvastatin and Omega-3 fatty acids treatment was more effective than Atorvastatin alone treatment in improving HDL-C levels from base line and it may have a additive effect in major coronary artery diseases.

Highlights

  • Hyperlipidemia patients have roughly twice the risk of developing Coronary Heart Disease (CHD) as compared to those with normal total cholesterol levels [1]

  • Statins use has shown strong evidence in preventing cardiovascular morbidity and mortality but still there is controversy due to conflicting results in various types of studies [2,3,4] According to WHO, an estimated 7.2 million people died from CHD in 2008, representing approximately 12% of deaths worldwide [5]

  • Total cholesterol levelswere significantly (p

Read more

Summary

Introduction

Hyperlipidemia patients have roughly twice the risk of developing Coronary Heart Disease (CHD) as compared to those with normal total cholesterol levels [1]. Among five lipoproteins LDL-C and HDL-C had a major role in increasing the risk of cardiovascular events, including myocardial infarction and stroke [7]. Omega-3 Fatty acids have demonstrated a preventiverole in primary and, secondary cardiovascular diseases. This study was planned to compare the efficacy of Atorvastatin alone with Atorvastatin and Omega-3 fatty acids in treatment in hyperlipidaemia patients. A total of 100 patients were selected based on inclusion and exclusion criteria. They were divided randomly into two Groups (Group–A and Group-B). Results: The results were compared before treatment and after 6 months treatment.The levels

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call